Bio-Thera is getting market advantage in China and Europe

Gennova completes Phase 2 and 3 trials of mRNA jab by January 2022

Excerpt

By the end of January next year, Gennova Biopharmaceuticals, a subsidiary of Emcure, a Pune-based pharmaceutical business that develops mRNACovid vaccines, will have completed Phase 2/3 studies and will apply to Indian drug regulators for an emergency use authorisation.

Article Summary

In 35 centres throughout India, Gennova has started Phase 2 and Phase 3 clinical trials of the mRNA-based vaccine HGCO19.

Unlike early COVID-19 vaccines like Covaxin and Covishield (AstraZeneca vaccine), which were evaluated against placebo in Phase 3, Gennova’s mRNA vaccine uses Covishield as a comparison, allowing testing to be completed faster.

CDSCO evaluated the safety and immunogenicity of the company’s mid-Phase 1 clinical trial results.

Unlike other mRNA vaccines that require temperatures above -20 ° C, Gennova’s mRNA vaccine is based on lyophilization technology, which allows storage at 2-8 ° C.

Emcure’s founder and CEO, Satish Mehta, said the company is also looking at the possibility of developing tuberculosis vaccines using the mRNA platform.

In addition to the COVID-19 vaccine, Gennova is employing the mRNA platform to develop vaccinations for deer, rabies, and herpes zoster.

Source: Gennova Biopharmaceuticals Ltd. , 2021

Get updates straight to your inbox

About The Author

IMAPAC is the one-stop shop of market intelligence and business connections for the global biopharmaceutical industry. We help companies expand their influence, make data driven decisions through our industry intelligence, and link up with other biopharmaceutical professionals to exchange knowledge and engage in quality networking. At the core of IMAPAC is our mission to help biopharmaceutical businesses globally generate tangible growth. At the same time, our heart lies in giving back to society. We empower the next generation by equipping underprivileged children with an education.